Olmesartan medoxomil-based therapy for the management of hypertension

Abstract

Contemporary practice guidelines for hypertension recommend a goal systolic/diastolic blood pressure (BP) of less than 140/90 mmHg for patients with hypertension and less than 130/80 mmHg for patients with diabetes mellitus or chronic kidney disease. Current guidelines recognize that most patients will require combination therapy to achieve these BP goals and recommend that the agents used in such therapy should have complementary mechanisms of action. Olmesartan medoxomil is an angiotensin receptor blocker approved for the treatment of hypertension as monotherapy or in combination with antihypertensive agents. It is also approved in a fixed-dose combination with hydrochlorothiazide or amlodipine. Olmesartan medoxomil-based therapy can manage hypertension across a range of patient types and has demonstrated good BP-lowering efficacy and goal attainment in individuals with stage 1 or stage 2 hypertension. The comparative antihypertensive efficacy and safety of olmesartan medoxomil, as monotherapy and as part of combination therapy, has been established in several large, randomized clinical trials. This review evaluates the chemistry, efficacy and safety of olmesartan medoxomil-based therapy and its expanding role in hypertension management.

Keywords::

• amlodipine
• combination
• efficacy
• hydrochlorothiazide
• hypertension
• olmesartan medoxomil
• safety

Financial & competing interests disclosure

M Greathouse has received speaking honoraria from Daiichi Sankyo, Inc. and honoraria for promotional programs from Forest Laboratories over the past year. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

Writing assistance was utilized in the production of this manuscript. The preparation of this article was supported by Daiichi Sankyo, Inc. M Greathouse would like to thank Blair Jarvis, Kathryn Leonard, BS, and Alan J Klopp, for providing editorial assistance in the preparation of this review.